BTIG Expects More Visibility for Cidara Therapeutics' (CDTX) CD101 Soon; Affirms at 'Buy'
Tweet Send to a Friend
BTIG affirms Cidara Therapeutics, Inc. (Nasdaq: CDTX) at Buy with a price target of $24 following recent quarterly results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
